Staging
Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
Cancers 2021 March 4 [Link] Kazuhiro Kitajima, Mitsunari Maruyama, Hiroyuki Yokoyama, Toshiyuki Minami, Takashi Yokoi, Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa, Koichiro Yamakado Abstract Background: To compare three FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) for response evaluation and prognosis prediction in…
Read MoreInvestigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…
Read MoreInvestigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…
Read MoreDiagnostic Laparoscopy Improves Staging of Malignant Pleural Mesothelioma with Routine PET Imaging
Annals of Thoracic Surgery 2020 December 1 [Link] R Taylor Ripley, Nihanth Palivela, Shawn S Groth, Eugene A Choi, Lorraine D Cornwell, Phillip W Carrott, George Van Buren, Taylor G Splawn, David J Sugarbaker, Bryan M Burt Abstract Background: With a multimodal treatment strategy, cytoreductive surgery extends survival in malignant pleural mesothelioma. Improving the accuracy…
Read MoreDynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
European Radiology 2018 July 2 [Link] Gudmundsson E, Labby Z, Straus CM, Sensakovic WF, Li F, Rose B, Cunliffe A, Kindler HL, Armato SG Abstract OBJECTIVES: The aim of this pilot study was to investigate the utility of haemodynamic parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT) scans in the assessment of tumour response to…
Read MoreTremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
The Lancet. Respiratory Medicine. 2018 May 14 [Link] Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M Abstract BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve…
Read MoreRevised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
Journal of Thoracic Oncology May 9 2018 [Link] Armato SG, Nowak AK Abstract Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. The current de-facto standard for the assessment of mesothelioma tumor response,…
Read MoreLoss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma
The American Journal of Surgical Pathology 2017 October [Epub ahead of print] [Link] Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC Abstract Distinguishing reactive mesothelial proliferation from malignant mesothelioma (MM) can be difficult, particularly on small biopsies. In this scenario, a diagnosis of…
Read MoreThe revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database
International Journal of Surgery 2017 October [Epub ahead of print] [Link] Wang S, Ma K, Wang Q, Sun F, Shi Y, Zhan C, Jiang W Abstract BACKGROUND: Several staging systems for MPM have been introduced. However, none of them provide perfect survival stratification among heterogeneous patients. The aim of this population-based cohort study was to…
Read MoreThe value of delayed phase enhanced imaging in malignant pleural mesothelioma
Journal of Thoracic Disease 2017 August [Link] Patel AM, et.al. Abstract BACKGROUND: Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance…
Read More